ESMO 2024 | Phase II trial of nivolumab to chemoradiotherapy in non-metastatic MIBC
Andromachi Kougioumtzopoulou, MD, MSc, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses a Phase II trial (NCT03993249) of nivolumab and trimodality therapy (TMT) with chemoradiotherapy (CRT) for non-metastatic muscle-invasive bladder cancer (nmMIBC) in patients unsuitable for or unwilling to undergo radical cystectomy. Results showed that nivolumab with CRT significantly improved 2-year relapse-free survival rate compared to CRT alone, with manageable adverse events. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
